Overview

Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia

Status:
Completed

Trial end date:
2019-09-24

Target enrollment:

Participant gender:

Summary

This is a Phase 2 study of SPR001 for the treatment of classic CAH that will provide 12 weeks of open-label treatment to eligible subjects.

Phase:

Phase 2

Details

Lead Sponsor:

Spruce Biosciences